Stock 000078 SHENZHEN NEPTUNUS BIOENGINEERING CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Shenzhen Neptunus Bioengineering Co., Ltd. Stock

Equities

000078

CNE000000X95

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
2.17 CNY 0.00% Intraday chart for Shenzhen Neptunus Bioengineering Co., Ltd. +2.84% -30.89%
2023 Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
2023 Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Financials

Sales 2021 41.05B 5.67B Sales 2022 37.83B 5.22B Capitalization 9.13B 1.26B
Net income 2021 93M 12.84M Net income 2022 -1.03B -142M EV / Sales 2021 0.44 x
Net Debt 2021 8.42B 1.16B Net Debt 2022 8.22B 1.13B EV / Sales 2022 0.46 x
P/E ratio 2021
88.3 x
P/E ratio 2022
-8.5 x
Employees 9,874
Yield 2021 *
-
Yield 2022
-
Free-Float 52.68%
More Fundamentals * Assessed data

Chart Shenzhen Neptunus Bioengineering Co., Ltd.

Dynamic Chart

Latest news about Shenzhen Neptunus Bioengineering Co., Ltd.

Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
UK Output Weakness Adds to BOE's Challenge DJ
Shenzhen Neptunus Bioengineering to Set Up 150 Million Yuan Medical Equipment Unit MT
FTSE 100 Closes Down 1.4% on US Credit Rating -2- DJ
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sector Update: Tech Stocks Edging Higher by Wednesday Close MT
Sector Update: Tech MT
FinVolution's Shares Fall Wednesday as Citigroup Downgrade Follows Lower Q4 Non-GAAP Earnings, Net Revenue MT
FinVolution Group's Q4 Non-GAAP Earnings Decline, Revenue Rises; CEO Steps Down; Annual Dividend Raised MT
Sterling May Fall Vs Euro as ECB More Aggressive -2- DJ
Shenzhen Neptunus Bioengineering Warns of Loss in 2022 MT
Sterling Could Turn Lower Vs Dollar After Recent Gains DJ
Shenzhen Neptunus Bioengineering Co., Ltd. Announces Executive Appointments CI
Shenzhen Neptunus Bioengineering Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
More news

Analyst Recommendations on Shenzhen Neptunus Bioengineering Co., Ltd.

FTSE 100 Closes Down 1.4% on US Credit Rating -2- DJ
More recommendations

Quotes and Performance

1 week+2.84%
Current month-10.70%
1 month-14.57%
3 months-23.86%
6 months-23.86%
Current year-30.89%
More quotes

Highs and lows

1 week
2.12
Extreme 2.12
2.20
1 month
2.09
Extreme 2.09
2.55
Current year
2.01
Extreme 2.01
3.51
1 year
2.01
Extreme 2.01
3.51
3 years
2.01
Extreme 2.01
4.14
5 years
2.01
Extreme 2.01
7.76
10 years
2.01
Extreme 2.01
14.39
More quotes

Managers and Directors - Shenzhen Neptunus Bioengineering Co., Ltd.

Managers TitleAgeSince
Feng Zhang PSD
 President 52 09-12-24
Da Kai Shen DFI
 Director of Finance/CFO 59 06-05-25
Rui Ying BRD
 Director/Board Member 40 22-10-30
Members of the board TitleAgeSince
Si Min Zhang CHM
 Chairman 62 92-12-12
Da Kai Shen DFI
 Director of Finance/CFO 59 06-05-25
Feng Zhang PSD
 President 52 09-12-24
More insiders

ETFs positioned on Shenzhen Neptunus Bioengineering Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
LEADERSHARES EQUITY SKEW ETF - USD ETF LeaderShares Equity Skew ETF - USD
0.00% 117 M€ +0.68% -
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD ETF Day Hagan/Ned Davis Research Smart Sector International ETF - USD
0.00% 31 M€ +3.05% -
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +2.35% -
More ETFs positioned on Shenzhen Neptunus Bioengineering Co., Ltd.

Quotes

Date Price Change Volume
24-04-24 2.17 0.00% 8,950,731
24-04-23 2.17 -0.46% 9,957,000
24-04-22 2.18 +1.40% 13,325,200
24-04-19 2.15 -0.46% 11,696,950
24-04-18 2.16 -1.82% 17,694,680

End-of-day quote Shenzhen S.E., April 23, 2024

More quotes

Company Profile

Shenzhen Neptunus Bioengineering Co.,Ltd is a China-based company principally engaged in pharmaceutical and food manufacturing and pharmaceutical commercial distribution businesses. The Company’s main products include anti-tumor products, cardiovascular drugs, marine drugs, respiratory drugs, anti-infective products and other pharmaceuticals, as well as healthcare products, health food and medical instrument. The Company distributes its products mainly in domestic market, with East China as its main market.
Sector
Pharmaceuticals
Calendar
2024-04-29 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
SHENZHEN NEPTUNUS BIOENGINEERING CO., LTD. Stock Shenzhen Neptunus Bioengineering Co., Ltd.
-30.89% 824M
MCKESSON CORPORATION Stock McKesson Corporation
+15.65% 69.91B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
+2.72% 25.14B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
+5.62% 8.32B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+6.10% 8.07B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-21.85% 7.97B
H. LUNDBECK A/S Stock H. Lundbeck A/S
+0.73% 4.56B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+17.40% 4.31B
EBOS GROUP LIMITED Stock EBOS Group Limited
-0.14% 3.99B
GALENICA AG Stock Galenica AG
-2.34% 3.87B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. 000078 Stock